Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 2:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 121 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Meningococcal vaccine Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Mucosal Immunity Against Neisseria Gonorrhoeae After 4CMenB Vaccination

NCT04722003
View directory record Official record
Conditions
Gonorrhoea
Interventions
Meningococcal Group B Vaccine, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Sep 21, 2026, 2:49 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age

NCT01659996
View directory record Official record
Conditions
Meningitis, Meningococcal Infection, Diphtheria, Tetanus, Pertussis, Haemophilus Influenzae Serotype b (Hib)
Interventions
Meningococcal polysaccharide diphtheria toxoid conjugate, Meningococcal polysaccharide diphtheria toxoid conjugate + Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
9 Months to 18 Months
Enrollment
1,394 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
56
States / cities
Birmingham, Alabama • Pinson, Alabama • Tucson, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Sep 21, 2026, 2:49 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®

NCT00355121
View directory record Official record
Conditions
Meningococcal Meningitis, Tetanus, Diphtheria, Pertussis, Poliomyelitis
Interventions
Polysaccharide Diphtheria Toxoid Conjugate Vaccine
Biological
Lead sponsor
Sanofi
Industry
Eligibility
4 Years to 7 Years
Enrollment
882 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
26
States / cities
Little Rock, Arkansas • Boulder, Colorado • Atlanta, Georgia + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2011 · Synced Sep 21, 2026, 2:49 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Safety of MenACWY-CRM Vaccination in Adolescents

NCT01452464
View directory record Official record
Conditions
Meningococcal Disease
Interventions
MenACWY-CRM
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
11 Years to 21 Years
Enrollment
55,397 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
3
States / cities
Riverside, California • San Diego, California • Valley Annex, 16994 E. Valley Blvd., Fontana, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2015 · Synced Sep 21, 2026, 2:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Meninigococcal Conjugate Vaccine Containing Serogroups A,C,Y,W and X (MCV5) in Healthy Adults

NCT02810340
View directory record Official record
Conditions
Meningococcal Vaccines
Interventions
Adjuvanted MCV-5, Non-Adjuvanted MCV-5, Menactra®
Biological
Lead sponsor
PATH
Other
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Sep 21, 2026, 2:49 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years

NCT01830855
View directory record Official record
Conditions
Meningococcal Vaccine
Interventions
rLP2086, Havrix (HAV), Saline
Biological
Lead sponsor
Pfizer
Industry
Eligibility
10 Years to 18 Years
Enrollment
3,596 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
62
States / cities
Birmingham, Alabama • Dothan, Alabama • Harrisburg, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2016 · Synced Sep 21, 2026, 2:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1 Safety and Immunogenicity of Meningococcal Vaccine

NCT00678652
View directory record Official record
Conditions
Meningococcal Infection, Group B
Interventions
10 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine, 25 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine, 50 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine, 75 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2017 · Synced Sep 21, 2026, 2:49 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae

NCT05294588
View directory record Official record
Conditions
Gonorrhea Male
Interventions
Cefixime, Ceftriaxone, Ciprofloxacin, Neisseria gonorrhoeae strain FA1090, Meningococcal Group B Vaccine, Influenza Vaccine, Tetanus-diptheria Vaccine
Drug · Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Sep 21, 2026, 2:49 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents

NCT02199691
View directory record Official record
Conditions
Meningitis, Meningococcal Meningitis, Meningococcal Infections
Interventions
Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine, Meningococcal (Groups A, C, Y and W135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine, Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed, GARDASIL®: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
10 Years to 17 Years
Enrollment
1,715 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
35
States / cities
Birmingham, Alabama • Huntsville, Alabama • Downey, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Sep 21, 2026, 2:49 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine

NCT00856297
View directory record Official record
Conditions
Meningococcal Meningitis
Interventions
MenACWY-CRM conjugate vaccine, Licensed comparator
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
11 Years to 18 Years
Enrollment
389 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
32
States / cities
Birmingham, Alabama • Fremont, California • Fresno, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Sep 21, 2026, 2:49 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Persistence of Protective Antibody Titers 12-24 Months After NmVac4-A/C/Y/W-135-DT Vaccination: Follow Up Study

NCT02500511
View directory record Official record
Conditions
Meningococcal Meningitis, Meningococcal Infections
Interventions
NmVac4-A/C/Y/W-135-DT™
Biological
Lead sponsor
JN-International Medical Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 11, 2016 · Synced Sep 21, 2026, 2:49 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Trial to Assess Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents

NCT02212457
View directory record Official record
Conditions
Infections, Meningococcal
Interventions
Bexsero, Saline Placebo, Havrix, MenABCWY
Biological · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
10 Years to 18 Years
Enrollment
1,063 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
13
States / cities
Jonesboro, Arkansas • Hialeah, Florida • Melbourne, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2019 · Synced Sep 21, 2026, 2:49 AM EDT
Not listed No phase listed Observational

National Vaccine Adverse Event Reporting Survey and Etiology

NCT05095844
View directory record Official record
Conditions
COVID-19, Vaccine Adverse Reaction, Vaccine Reaction, Vaccine or Biological Substance, Unspecified Causing Adverse Effects in Therapeutic Use, Corona Virus Infection, Blood Clot, Thrombocytopenia, Neuritis, Vasculitis, Influenza, Guillain-Barré, GWAS, Genetic Sequencing
Interventions
vaccinated
Biological
Lead sponsor
Neuroganics LLC
Industry
Eligibility
5 Years to 99 Years
Enrollment
100,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Northglenn, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Sep 21, 2026, 2:49 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of a Single Dose of Menactra® Vaccine 4-6 Years After Prior Menactra Vaccine

NCT01442675
View directory record Official record
Conditions
Meningitis, Meningococcal Infection
Interventions
Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate: Menactra®
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
15 Years to 55 Years
Enrollment
834 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
15
States / cities
Little Rock, Arkansas • San Diego, California • Bardstown, Kentucky + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2014 · Synced Sep 21, 2026, 2:49 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants

NCT03621670
View directory record Official record
Conditions
Infections, Meningococcal
Interventions
Bexsero (GSK Biologicals' Meningococcal group-B vaccine/ rMenB+OMV NZ), Prevnar13, Pediarix, Hiberix, Rotarix, M-M-R II, Varivax, Placebo (saline water), Prevnar 20
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
1,196 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
56
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 21, 2026, 2:49 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of Meningococcal Vaccine GSK134612 Given as 1 or 2 Doses to Healthy 9-12 Months Old Toddlers.

NCT00471081
View directory record Official record
Conditions
Infections, Meningococcal
Interventions
Meningococcal vaccine GSK134612
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
9 Months to 9 Months
Enrollment
385 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
19
States / cities
Birmingham, Alabama • Benton, Arkansas • Little Rock, Arkansas + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2019 · Synced Sep 21, 2026, 2:49 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine

NCT02842853
View directory record Official record
Conditions
Meningitis, Meningococcal Meningitis, Meningococcal Infections
Interventions
Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine, Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
10 Years to 55 Years
Enrollment
3,344 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
89
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 72 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Sep 21, 2026, 2:49 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study of the Safety and Immune Response of Two Serogroup B Meningococcal Vaccines Administered to Healthy Adolescents

NCT00297817
View directory record Official record
Conditions
Meningococcal Disease
Interventions
serogroup B meningococcal vaccine
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
11 Years to 18 Years
Enrollment
203 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
8
States / cities
Encinitas, California • Atlanta, Georgia • St Louis, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2016 · Synced Sep 21, 2026, 2:49 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers

NCT00384397
View directory record Official record
Conditions
Meningococcal Meningitis, Measles, Mumps, Rubella, Varicella
Interventions
Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine, Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
249 Days to 305 Days
Enrollment
1,128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
39
States / cities
Montgomery, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 35 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Sep 21, 2026, 2:49 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety of and Immune Response to a Meningitis Vaccine in HIV-Infected Children and Youth

NCT00459316
View directory record Official record
Conditions
HIV Infections, Meningitis
Interventions
Quadrivalent meningococcal conjugate vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 24 Years
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
35
States / cities
Alhambra, California • Long Beach, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Sep 21, 2026, 2:49 AM EDT
Completed Phase 2 Interventional Results available

Study of the Safety and Immune Response of a Meningococcal Conjugate Vaccine Administered to Healthy Adolescents

NCT00262041
View directory record Official record
Conditions
Prevention of Meningococcal Disease
Interventions
MenACWY-CRM conjugate vaccine, adjuvanted, MenACWY-CRM conjugate vaccine, unadjuvanted, MenACWY polysaccharide vaccine
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
11 Years to 17 Years
Enrollment
524 participants
Timeline
2004 – 2006
U.S. locations
3
States / cities
Rochester, Minnesota • Pittsburgh, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Sep 21, 2026, 2:49 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Strengthening Physician Communication About HPV Vaccines

NCT02456077
View directory record Official record
Conditions
HPV Immunization Status
Interventions
Multimodal Vaccine Program
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
9 Years and older
Enrollment
93,582 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 23, 2019 · Synced Sep 21, 2026, 2:49 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Toddlers

NCT00718666
View directory record Official record
Conditions
Infections, Meningococcal
Interventions
Meningococcal vaccine GSK134612
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
2 Years to 6 Years
Enrollment
387 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
14
States / cities
Benton, Arkansas • Little Rock, Arkansas • Antioch, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Sep 21, 2026, 2:49 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults

NCT01165242
View directory record Official record
Conditions
Infections, Meningococcal
Interventions
Meningococcal vaccine GSK 134612, Menactra®
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
10 Years to 25 Years
Enrollment
1,013 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
24
States / cities
Chandler, Arizona • Paramount, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced Sep 21, 2026, 2:49 AM EDT